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Immune tolerance considered to be a holy grail for long-term graft survival of organ 
transplants. However, the current methodologies, agents and strategies have failed to 
achieve measurable immune tolerance. Therefore, there is a need to discover alternate 
mediators and pathways that mediate the events leading to immune tolerance. Since 
aberrant proliferation is considered to be the barrier to immune tolerance, molecules that 
control cell cycle progression may be the key components in this process. Cyclin kinase 
inhibitor p21 is such a molecule, which is potent regulator of the events of cellular 
proliferation and apoptosis1, 2, the key determinants of immune tolerance. We have shown 
that cyclins and p21 play reciprocal role in immune activation and inflammation3. 
Additionally, our studies have demonstrated that in vitro and in vivo over-expression of 
p21 renders lymphocytes less responsive to mitogenic stimuli, decrease inflammation and 
prolong graft survival 4, 5. We have also reported that recombinant p21 protein interacts in 
vivo with transcription factors, inhibits lymphocyte proliferation and inflammation 6.  In 
this study, we demonstrate that p21 by virtue of its properties similar to CD4+CD25+ T 
regulator cells may be a key component of the process of immune tolerance. 
The results from wild type [n =9] and p21-/- mice [n = 9] are shown in Figure 1 A.  
The splenocytes from p21-/- mice proliferated significantly [p<0.01] more compared to 
wild -type mice.  We also studied the effect of cyclosporine [CsA], on the proliferation of 
lymphocytes from wild type and p21-/- mice.  To determine if the increased proliferation 
of p21-/- mice is the direct effect of p21 deficiency, the expression of p21 was induced in 
p21-/- mice; using our previously described procedure4.  We injected mice with either p21 
sense or empty vector plasmid DNA [intramuscularly] two times at an interval of 5 days.  
Mice were sacrificed 7 and 21 days after the last injection [n=4 in each group].   Figure 
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1C demonstrates that the transfection of p21 in p21-/- mice resulted in a significantly 
decreased proliferation in response to anti-CD3, although more inhibition after 7 days 
compared to 21 days.  Since there is a parallel between the expression of cyclins and pro-
inflammatory genes3 and FoxP3 is an indicator of tolerance associated with decreased 
lymphocyte proliferation, we also studied expression of cyclin G and pro-inflammatory 
cytokines IFN-γ and TNF-α mRNA expression and its effect on FoxP3 mRNA 
expression.  Lymphocytes from p21-/- mice with and without p21 overexpression were 
activated with anti-CD3. RNA were prepared, reverse transcribed to cDNA and amplified 
for cyclin G, IFN-γ, TNF-α and FoxP3 mRNA by Real Time-PCR. The mRNA 
expression of cyclin G [p<0.02], IFN-γ [p<0.05] and TNF-α [p<0.04] decreased 
significantly in anti-CD3 stimulated splenocytes from p21 transfected p21-/- mice 
compared to the p21-/- mice transfected with the control plasmid DNA. However, a 
significant increase in FoxP3 mRNA was observed. These results [Figure 1D] 
demonstrate that the expression of p21 in p21-/- mice inhibit the expression of cyclins and 
of pro-inflammatory cytokines and promote FoxP3 expression, suggesting shifting a 
balance toward CD4+CD25+ T regulatory cells.   
               The above described results demonstrate that p21 deficiency results in increased 
proliferation of lymphocytes, mRNA expression of pro-inflammatory cytokines and 
therefore, we determined if this effect is due to the imbalance of CD4+CD25+ and 
CD4+CD25- cells.  We quantified CD4+CD25+ and CD4+CD25- T cells in spleen cells 
obtained from wild -type and p21-/- mice.   The fluocytometric analysis demonstrated that 
in CD4+CD25+ cells comprised to 14.5± 1.6 in wild type mice and 2.6 ± 0.8 percent of 
total cells in p21-/-mice, which were significantly [p<0.002] lower in these mice [Figure 
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2A]. These results suggest that lack of p21 results in increased lymphocyte proliferation 
due to diminished number of CD4+CD25+ T regulatory cells.  Since FoxP3 mRNA 
expression is expressed only on CD4+CD25+ but not CD4+CD25- T cells, we 
determined and quantified mRNA expression of FoxP3 in these cells isolated from wild 
type and p21-/- mice. The results from a representative of three p21-/- and wild type mice 
demonstrates that FoxP3 expression was observed only in splenocytes from wild type and 
not from p21-/- mice [Figure 2 B].  These results suggest that p21-/- mice have 
significantly lower number of CD4+CD25+ T regulatory cells that was reflected by 
FoxP3 mRNA in splenocytes. To confirm these results, using Real Time PCR analysis, 
we quantified FoxP3 mRNA in CD4+ T cell subsets; CD4+CD25+ and CD4+CD25- T 
cells.  The results [Figure 2C] demonstrate that amplification was observed only in 
CD4+CD23+ but not in CD4+CD25- T cells. Identical amplification of β-actin mRNA 
was observed in these cDNA samples. We also calculated fold expression in these CD4+ 
T cell subsets using β-actin as reference gene and a in built formula 2[[Ct/beta-actin − 
Ct/gene of interest]].. The results shown in Figure 2D demonstrate that CD+CD25+ 
expressed about 40 fold increased FoxP3 mRNA compared to CD4+CD25- T cells in a 
single sample, mean ± SEM of relative fold expression from 6 such experiments is shown 
in Figure 2E, indicate a significantly higher expression of FoxP3 mRNA in CD4+CD25+ 
T cells from wild type mice compared to p21-/- mice. These results confirm the fewer 
number of FoxP3+ CD4+CD25+ T cells in p21-/- mice compared to wild type mice. More 
significantly, co-cultured CD4+CD25+ cells from wild type and p21-/- mice exhibited 
increased FoxP3 mRNA in an autologous MLR assay.   
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These results described above suggest that the characteristics of p21 deficient 
cells are similar to CD4+CD25- T cells with respect to the deficiency of FoxP3 mRNA 
To compare and contrast the immunological characteristics of p21 deficient and p21 
expressing with CD4+CD25+/- T regulatory cells., experiments were planned.   We 
compared n the proliferation of purified CD4+CD25- and CD4+CD25+ T cells [n=6]. 
The difference in proliferation [counts per minute] among CD4+CD25+ [15236 ± 1190] 
and CD4+CD25- [50317 ± 974] T-cells was highly significant [p<0.003].   These results 
[Figure 3A] are similar to those observed with splenocytes from wild type and p21-/- 
mice [Figure 1A], suggesting that the immunological response of p21 expressing, 
CD4+CD25+ and p21 deficient, CD4+CD25- cells  to mitogenic stimuli is similar.  
Similar to p21 deficient lymphocytes [Figure 1B], anti-CD3 activated CD4+CD25- T 
cells were not responsive to the inhibitory effects of CsA [Figure 3B]. This similarity can 
only be explained due to the inability of CsA to induce p21 expression in both p21 
deficient and CD4+CD25- T cells, additionally, it also suggest an interaction between 
p21 and FoxP3.  We performed experiments on CD4+CD25+ and CD4+CD25- T cells to 
understand if p21 plays any role in the function of these cells.   We analyzed TGF-β and 
p21 mRNA in CD4+CD25+ and CD4+CD25- T cells activated with and without CsA. 
The results demonstrate that CsA induced TGF-β and p21 mRNA expression in 
CD4+CD25+ T cells [Figure 3C,] but not in CD4+ CD25- T cells [Figure 3D]. These 
results suggest that TGF-β and p21 play a significant role in the function of CD4+CD25+ 
T cells.  Therefore, these results suggest that the inability of these cells to induce 
expression of either TGF-β or p21, the most powerful anti-proliferative molecules may 
contribute to heightened proliferative response of CD4+CD25- and p21-/- lymphocytes.   
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We also performed studies to understand if similar to the reported inhibition of 
proliferation of CD4+CD25t- T cells by CD4+CD25+ T cells, wild type [p21 expressing] 
T cells will inhibit proliferation of T lymphocytes from p21-/- mice.  We performed an 
autologous MLR assay using lymphocytes from either WT or p21 deficient cells as 
responder or stimulators. The results were compared with CD4+CD25+ and CD4+CD25- 
T lymphocytes. The results shown in the Figure 4A demonstrate that the proliferation of 
CD4+CD25+/ CD4+CD25- T cells is in the median range of these cells alone, indicating 
that CD4+CD25+ induce inhibitory response in CD4+CD25- T cells.  These results were 
complemented by an almost median expression of T regulatory cells specific gene 
expression for Foxp3, ILT3 and GITR [Figure 4B].  Results in Figure 4C demonstrate 
that in an autologous MLR assay, an inhibition of proliferation lymphocytes from p21-/- 
mice was observed when lymphocytes from WT mice that express p21 were used as 
stimulators. These results are similar to those observed with CD4+CD25+ and 
CD4+CD25- T cells and identical pattern of FoxP3 mRNA was observed in p21 
expressing, p21-/- and mixture of these cells after MLR assay [Figures 4A and 4C].  
FoxP3 mRNA in these cells confirms the immunological response of these subsets of 
lymphocytes from wild type and p21-/- mice in autologous MLR assay [Figure 4D]. 
The results from this study demonstrate that the immunological responses of p21 
deficient lymphocytes and CD4+CD25- T regulatory lymphocytes are similar.  Our 
earlier studies have demonstrated that in vitro and in vivo over-expression of p21 renders 
lymphocytes less responsive to allo-and mitogen-induced proliferation and prolongs 
allograft survival in a rat heart transplant mode4, 5.  Analysis of the consequences of 
CD4+CD25+ T cell and p21 deficiency demonstrates a close similarity regarding 
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increased immune activation; break in tolerance and development of lupus occurs9, 10.  
Therefore, p21 may play a crucial role in the generation of T regulatory cells. We 
exploited this strong association between FoxP3 expression and regulatory function in 
p21 deficient lymphocytes and CD4+CD25- T cells. .It is believed that CD4+CD25+ 
regulatory T cells [Treg’s] play a key role in inducing tolerance to allogeneic organ 
transplants. TGF-β plays a pivotal role in suppression of lymphocyte proliferation by 
Treg’s and effectively diminishes inflammation and negatively regulates immune 
functions by inducing cell anergy9. TGF-β also induces the expression of Foxp3, a 
molecule associated with the development of Treg’s11. Though numbers of such studies 
have highlighted the role of TGF-β in the generation and maintenance of Treg’s, this 
does not seem to be universally true. CD4+CD25+ regulatory T cells developed in 
complete absence of endogenous TGF-β expression, and that autocrine TGF-β expression 
was not necessary for these cells to suppress inflammation in vivo12-14 as the 
neutralization of TGF-β with either monoclonal antibody [mAb] or soluble TGF-β RII-Fc 
failed to reverse in vitro suppression mediated by resting or activated CD4+ CD25+ T 
cells. Responder T cells from Smad3 -/- or dominant-negative TGF-β type RII transgenic 
[DNRIITg] mice, both unresponsive to TGF-β-induced growth arrest, were as susceptible 
to CD4+CD25+-mediated suppression as T cells from wild-type mice. Furthermore, 
CD4+CD25+ T cells from neonatal TGF-β-/- mice were functionally not different from 
TGF-beta1+/+ mice15,16. Therefore, CD4+CD25+ suppressor function can occur 
independently of TGF-β, .  Since TGF-β’s anti-proliferative effects are mediated by p21, 
we speculated that these effects of TGF-β may be via induction of p21.  
 8
Other studies also indicate similarities between cells deficient in p21 and 
CD4+CD25+ population, the deficiency of p21 and CD4+CD25+ cells17-23 results in the 
development of spontaneous lupus-like disease.  The deficiency of p21 resulted in 
immune activation, homeostatic proliferation and manifestation of lupus-like disease.  
These findings were supported by studies17-18, which demonstrated that the p21-/- mice 
have increased lymphocyte activation, antibodies against dsDNA, lymphoadenopathy and 
glomerulonephritis similar to lupus patients.  A mimic of p21 that negatively regulated T 
cell proliferation exhibited protective effects in a mouse model of lupus24. TGF-β’s anti 
proliferative effects are mediated by cyclin inhibitor p21 and our studies have 
demonstrated that CsA and tacrolimus induce p21’s gene and protein expression, which 
is dependent on TGF-β expression7, 25. We have reported4, 5 that in vitro and in vivo 
overexpression of p21 decreased response of mitogens on lymphocyte proliferation and 
increased responsiveness to the antiproliferative effects of CsA.  Therefore, it is plausible 
that p21 plays a significant role in the generation of T regulatory cells.   
Apoptosis is one of the critical events in maintaining immune tolerance to self and 
non-self antigens. It is likely that inhibition of apoptosis in lymphocytes leads to break in 
tolerance, alloimmune activation and inflammation26. This is supported by the role of 
dendritic cells [DC] in tolerance27. Induction of apoptosis in T cells treated with co-
stimulatory block and sirolimus paralleled with tolerance28, 29, the mechanism of this is 
not clear but lymphocyte undergoing apoptosis have been shown to secrete anti-
inflammatory molecules such as IL-10 and TGF-beta30 known to be the inducers of T 
regulatory cells. Interestingly, this role of apoptosis in induction of tolerance fits well in 
support of the role p21 in this process. The role of p21 in induction of apoptosis in cancer 
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cells31 and T lymphocytes32 has been related to its anti-proliferative effects. Furthermore, 
in p21 transgene mice restricted to the T cell lineage, T cells were more responsive to cell 
death confirming the proapoptotic effect of p2133. Based on these results p21 seems to 
mediate generation of T Regs and immune tolerance. 
Interestingly, our interesting findings can also be explained with number of factors such 
as therapeutic agents and transcription factors such as HDAC inhibitors, RUNX 
transcription factors, and nuclear factor of activated T cells [NFAT] that interact with 
both p21 and FoxP3. HDAC inhibitors [HDACi] have been shown to increase Foxp3 
expression through enhancing the numbers and functions of Foxp3+ CD4+CD25+ T 
regulatory cells, suggesting the possibility of increasing the suppressive properties of T 
regulatory cells using pharmacologically agents34.  Interestingly, several studies have 
shown that HDAC inhibitors strongly activate the expression of p2135-37. Thus, our 
studies show important new mechanisms by which HDACis can modulate inflammatory 
and immune responses in vivo through the induction of T regulatory cells possibly 
mediated by the induction of p21. Since it is known that the inhibition of HDAC in vitro 
and in vivo increases the numbers of Foxp3+ T cells and there is a direct relationship 
between the presence of p21 and FoxP3+ cells, it is again suggesting that p21 regulates 
the function of T regulatory cells.  Other studies38 have observed the histone deacetylase 
[HDAC] inhibitors [phenylbutyrate and trichostatin A] by hyperacetylation of histone not 
only induced the expression of p21 in synovial cells but also inhibited the expression of 
tumor necrosis factor-alpha in affected tissues in adjuvant arthritis, an animal model of 
RA.  Nuclear factor of activated cells [NFAT] also interacts with Foxp3 and Runx139, 
which involved TIP60 to facilitate FoxP3 complex-mediated repression of IL-2 
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production. TIP60 is known to induce expression of p21 asTip60 knockdown inhibited 
induction of p21 and its over-expression resulted in increase p21 expression levels in 
293T cells40-41.   NFAT components, NFATc and NFATp with opposite functions also 
regulate expression of FoxP3 negatively and positively, respectively. Our studies have 
shown that the suppression of T cell proliferation by recombinant p21 protein results in 
an increased NFATp and decreased NFATc expression that correlated with IL-2 
expression6.  These results suggest that p21 may mediate the suppression of T 
lymphocyte proliferation through FoxP3 positive T regulatory cells. Similarly, RUNX 
Runx1 [Runt-related transcription factors], which is crucially required for normal 
hematopoiesis including thymic T-cell development also participate in generation of 
FoxP3 cells, suppression or activation of cellular proliferation and the actions include the 
relevant activity of both FoxP3 and p2142-44. Members of RUNX family RUNX 1, 2 and 
3 have distinctive functions. Additionally, Foxp3 also interacts with two other members 
of the AML/Runx protein family, AML2 [Runx3] and AML3 [Runx2], albeit in different 
ways, its interaction with RUNX3 is positive and RUNX2 is negative on cellular 
proliferation including hematopoietic, immune and cancer cells.  The effect on immune 
system and interaction between RUNX family members is reflected by their stimulatory 
and suppressive effects on p21. More recently45, p21 was shown to be a downstream 
target for FoxP3, because it served as an important target for all major tumor suppressor 
genes and the authors speculated the possibility of reactivation of p21 in cancer by 
inducing FoxP3. These results are supportive of our findings suggesting that the 
activation of FoxP3 by p21 may prove to be a more relevant to the development of 
immune tolerance. 
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The results therefore, signify the possible therapeutic potential of p21 in 
induction/generation of T regulatory cells in the recipients providing a milieu for immune 
tolerance in organ transplantation.  
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Figure Legends: 
Figure 1: Effect of cyclin kinase inhibitor p21 modulation on lymphocyte 
proliferation and inflammation. A: A statistical significant [p<0.001] increased 
proliferation of splenocytes from p21-/- [closed bars] compared to WT mice [open bars] is 
shown. B: Inhibition of proliferation of activated splenocytes was observed only in WT 
and not p21-/- mice. C: Statistically significant [p<0.01] decreased proliferation in p21 
gene restored p21-/- mice is shown after one [closed bars] and three [gray bars] is shown. 
D: Overexpression of p21 significantly decreased cyclin G [p<0.02], IFN-gamma 
[p<0.05], TNF-alpha [p<0.04] and increased FoxP3 [p<0.03] mRNA expression 
Figure 2: Quantification of CD4+CD25+ T cells and FoxP3 mRNA expression in 
WT and p21-/- mice. A: Significantly [p<0.002] lower number of CD4+CD25+ T cells 
is shown in p21-/- compared to WT mice. B: Expression of FoxP3 mRNA is seen only in 
splenocytes from WT but not p21-/- mice. Similar expression of house-keeping gene -
actin is shown. C:  Amplification for FoxP3 mRNA was seen only with CD4+CD25+ T 
cells, analysis of mRNA expression normalized to β-actin is shown in D, and E: Mean ± 
SEM of normalized fold expression of FoxP3 mRNA in CD4+CD25+, CD4+CD25- and 
mixture of CD4+CD25+ T cells from both mice is shown in E. 
Figure 3: Differential response of CD4+CD25+ and CD4+CD25- T cells to mitogenic 
stimuli: A: CD4+CD25- T cells proliferated significantly higher [p<0.001] compared to 
CD4+CD25+ cells in response to anti-CD3 antibody. B: Proliferation of CD4+CD25+ 
not CD4+CD25- T cells was inhibited by CsA. CD4+CD25+ T cells [C] not CD4+25- 
activated T cells induced TGF-β and p21 mRNA [D] in response to CsA. 
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Figure 4:  Similarities between proliferation responses of CD4+CD25+, CD4+CD25-
, and immune cells from WT and p21-/- mice:  A: CD4+CD25+, CD4+CD25- or a 
mixture [1:1] of CD4+CD25+/- T cells were activated with anti-CD3 antibody, 
Cd4+CD25- T cells proliferated higher than CD4+CD25+ cells and the proliferation of 
the mixture of CD4+CD25+/- T cells was almost in the median range. B: mRNA 
expression of T regulatory specific markers FoxP3, ILT3 and GITR reflects the 
differential proliferation of CD4+CD25+, CD4+CD25- and mixture of these cells. C:  
Results from autologous MLR assay using splenocytes from wild type and p21-/- mice as 
responder and stimulators, Gray Bars; WT stimulators and responders, Closed Bars; p21-/- 
stimulator and responder; Open Bars: WT stimulator+ p21-/- responders. WT stimulator 
splenocytes decreased proliferation of p21-/- splenocytes. D: FoxP3 mRNA expression 
correlates with inhibitory effects of WT splenocytes on p21-/- splenocytes in an 
autologous MLR assay. 
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